# Pharmacogenetics of Torasemide and Spironolactone in Hypertension Treatment

> **NCT06413082** · PHASE3 · COMPLETED · sponsor: **Ospedale San Raffaele** · enrollment: 38 (actual)

## Conditions studied

- Hypertension
- Genetic Predisposition
- Drug Effect

## Interventions

- **DRUG:** Torasemide
- **DRUG:** Spironolactone

## Key facts

- **NCT ID:** NCT06413082
- **Lead sponsor:** Ospedale San Raffaele
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-15
- **Primary completion:** 2023-07-07
- **Final completion:** 2023-09-03
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2024-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06413082

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06413082, "Pharmacogenetics of Torasemide and Spironolactone in Hypertension Treatment". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT06413082. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*